
What smart money is saying about Vitrafy Life Sciences
1 fund in our archive has pitched Vitrafy Life Sciences — most recently Ryder Capital Limited in September 2026.
Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
Get an email when a fund buys, sells or pitches it
Position history
Every position in Vitrafy Life Sciences on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsRyder Capital LimitedSeptember 2026
“Vitrafy – 7.25% Portfolio Weight Vitrafy rose 32.9% over the quarter following a well-supported $30m placement in June resulting in a healthy closing cash position of $41.2m.”
Vitrafy Life Sciences
Fund coverage · 1 thesis
- Ryder Capital LimitedSeptember 2026
Vitrafy Life Sciences is building validation across blood banking and cell therapy markets, with partnerships and funding supporting near-term commercialization.
Read the full thesis
Read every full thesis on Vitrafy Life Sciences
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→